248 related articles for article (PubMed ID: 23375777)
1. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.
Singh A; Lun X; Jayanthan A; Obaid H; Ruan Y; Strother D; Chi SN; Smith A; Forsyth P; Narendran A
Mol Oncol; 2013 Jun; 7(3):497-512. PubMed ID: 23375777
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors.
Obaid H; Kannappan S; Gupta M; Ruan Y; Zhang C; Bose P; Narendran A
Curr Cancer Drug Targets; 2020; 20(4):295-305. PubMed ID: 31713485
[TBL] [Abstract][Full Text] [Related]
3. A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
Fouladi M; Stewart CF; Blaney SM; Onar-Thomas A; Schaiquevich P; Packer RJ; Goldman S; Geyer JR; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
J Neurooncol; 2013 Sep; 114(2):173-9. PubMed ID: 23836190
[TBL] [Abstract][Full Text] [Related]
4. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
[TBL] [Abstract][Full Text] [Related]
5. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.
Ammoun S; Cunliffe CH; Allen JC; Chiriboga L; Giancotti FG; Zagzag D; Hanemann CO; Karajannis MA
Neuro Oncol; 2010 Aug; 12(8):834-43. PubMed ID: 20511180
[TBL] [Abstract][Full Text] [Related]
6. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
[TBL] [Abstract][Full Text] [Related]
7. Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor.
Giang LH; Wu KS; Lee WC; Chu SS; Do AD; Changou CA; Tran HM; Hsieh TH; Chen HH; Hsieh CL; Sung SY; Yu AL; Yen Y; Wong TT; Chang CC
J Exp Clin Cancer Res; 2023 Dec; 42(1):346. PubMed ID: 38124207
[TBL] [Abstract][Full Text] [Related]
8. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.
Qi L; Zhang B; Zhang S; Ci X; Wu Q; Ma G; Luo A; Fu L; King JL; Nahta R; Dong JT
Oncotarget; 2017 May; 8(22):36054-36066. PubMed ID: 28415602
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Targeting of PTK7 is Cytotoxic in Atypical Teratoid Rhabdoid Tumors.
Messerli SM; Hoffman MM; Gnimpieba EZ; Bhardwaj RD
Mol Cancer Res; 2017 Aug; 15(8):973-983. PubMed ID: 28442586
[TBL] [Abstract][Full Text] [Related]
10. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.
Konecny GE; Venkatesan N; Yang G; Dering J; Ginther C; Finn R; Rahmeh M; Fejzo MS; Toft D; Jiang SW; Slamon DJ; Podratz KC
Br J Cancer; 2008 Mar; 98(6):1076-84. PubMed ID: 18334972
[TBL] [Abstract][Full Text] [Related]
11. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.
Gorlick R; Kolb EA; Houghton PJ; Morton CL; Phelps D; Schaiquevich P; Stewart C; Keir ST; Lock R; Carol H; Reynolds CP; Maris JM; Wu J; Smith MA
Pediatr Blood Cancer; 2009 Oct; 53(4):594-8. PubMed ID: 19554571
[TBL] [Abstract][Full Text] [Related]
12. Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells.
D'cunja J; Shalaby T; Rivera P; von Büren A; Patti R; Heppner FL; Arcaro A; Rorke-Adams LB; Phillips PC; Grotzer MA
Eur J Cancer; 2007 Jul; 43(10):1581-9. PubMed ID: 17446062
[TBL] [Abstract][Full Text] [Related]
13. Atypical teratoid/rhabdoid tumor of the CNS: cytopathology and immunohistochemistry of insulin-like growth factor-II, insulin-like growth factor receptor type 1, cathepsin D, and Ki-67.
Ogino S; Cohen ML; Abdul-Karim FW
Mod Pathol; 1999 Apr; 12(4):379-85. PubMed ID: 10229502
[TBL] [Abstract][Full Text] [Related]
14. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A
BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769
[TBL] [Abstract][Full Text] [Related]
15. Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells.
Venkataraman S; Alimova I; Tello T; Harris PS; Knipstein JA; Donson AM; Foreman NK; Liu AK; Vibhakar R
J Neurooncol; 2012 May; 107(3):517-26. PubMed ID: 22246202
[TBL] [Abstract][Full Text] [Related]
16. Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.
Havaleshko DM; Smith SC; Cho H; Cheon S; Owens CR; Lee JK; Liotta LA; Espina V; Wulfkuhle JD; Petricoin EF; Theodorescu D
Neoplasia; 2009 Nov; 11(11):1185-93. PubMed ID: 19881954
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.
Liu T; Yacoub R; Taliaferro-Smith LD; Sun SY; Graham TR; Dolan R; Lobo C; Tighiouart M; Yang L; Adams A; O'Regan RM
Mol Cancer Ther; 2011 Aug; 10(8):1460-9. PubMed ID: 21690228
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells.
Knipstein JA; Birks DK; Donson AM; Alimova I; Foreman NK; Vibhakar R
Neuro Oncol; 2012 Feb; 14(2):175-83. PubMed ID: 22156471
[TBL] [Abstract][Full Text] [Related]
19. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
[TBL] [Abstract][Full Text] [Related]
20. Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors.
Alimova I; Wang D; Danis E; Pierce A; Donson A; Serkova N; Madhavan K; Lakshmanachetty S; Balakrishnan I; Foreman NK; Mitra S; Venkataraman S; Vibhakar R
Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35179215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
